S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
S&P 500   3,213.25 (-0.41%)
DOW   26,748.00 (-0.45%)
QQQ   257.88 (-1.16%)
AAPL   384.00 (-1.77%)
MSFT   203.74 (-2.07%)
FB   238.86 (-0.59%)
GOOGL   1,502.65 (-0.94%)
AMZN   2,996.28 (-0.42%)
NVDA   402.96 (-1.50%)
CGC   17.99 (-0.88%)
BABA   243.17 (-2.42%)
MU   49.91 (-1.19%)
GE   7.10 (-0.56%)
TSLA   1,517.22 (-1.86%)
AMD   54.49 (-1.54%)
T   30.32 (+1.03%)
ACB   12.19 (-5.28%)
F   6.79 (+0.74%)
GILD   76.08 (-0.74%)
DIS   119.37 (-1.27%)
NFLX   524.30 (+0.20%)
BAC   24.00 (-2.44%)
BA   180.55 (-3.93%)
Log in

NASDAQ:ERYPErytech Pharma Stock Price, Forecast & News

$7.68
+0.75 (+10.83 %)
(As of 07/16/2020 01:13 PM ET)
Add
Compare
Today's Range
$7.33
Now: $7.68
$7.89
50-Day Range
$7.60
MA: $8.73
$10.22
52-Week Range
$3.50
Now: $7.68
$12.00
Volume2,341 shs
Average Volume1,707 shs
Market Capitalization$137.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Read More
Erytech Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.25 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ERYP
CUSIPN/A
CIKN/A
Phone33-4-78-74-44-38

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.34 per share

Profitability

Miscellaneous

Employees172
Market Cap$137.69 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.

Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions

How has Erytech Pharma's stock been impacted by COVID-19 (Coronavirus)?

Erytech Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ERYP stock has increased by 46.5% and is now trading at $7.6750. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Erytech Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Erytech Pharma.

What price target have analysts set for ERYP?

2 brokers have issued 12-month price targets for Erytech Pharma's shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Erytech Pharma's stock price to reach $13.00 in the next year. This suggests a possible upside of 69.4% from the stock's current price. View analysts' price targets for Erytech Pharma.

Has Erytech Pharma been receiving favorable news coverage?

Headlines about ERYP stock have been trending positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Erytech Pharma earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news about Erytech Pharma.

Are investors shorting Erytech Pharma?

Erytech Pharma saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,000 shares, a decrease of 33.3% from the June 15th total of 1,500 shares. Based on an average daily trading volume, of 4,200 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the shares of the company are short sold. View Erytech Pharma's Current Options Chain.

Who are some of Erytech Pharma's key competitors?

What other stocks do shareholders of Erytech Pharma own?

Who are Erytech Pharma's key executives?

Erytech Pharma's management team includes the following people:
  • Mr. Gil Beyen, Chairman & CEO (Age 57)
  • Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
  • Mr. Eric Soyer, CFO & COO (Age 53)
  • Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
  • Naomi Eichenbaum, Director Investor Relations

When did Erytech Pharma IPO?

(ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Erytech Pharma's stock symbol?

Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."

How do I buy shares of Erytech Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Erytech Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $7.68.

How big of a company is Erytech Pharma?

Erytech Pharma has a market capitalization of $137.69 million. The company earns $-70,180,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Erytech Pharma employs 172 workers across the globe.

What is Erytech Pharma's official website?

The official website for Erytech Pharma is www.erytech.com.

How can I contact Erytech Pharma?

Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.